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Abstract: MiR-21 has been linked to tumorigenesis, development, and metastasis in 
tumor pathogenesis. All human cancers, including breast cancer, have increased 
expression of MiR-21, which is the only miRNA that has increased expression. PTEN 
expression was found to be reduced in the majority of solid tumors, including breast 
cancer. Since lymph node metastatic factors, estrogen receptor status, tumor grade, and 
tumor node metastasis (TNM) all decreased PTEN expression, the PTEN expression 
profile may be a very useful prognostic marker in breast cancer. PTEN inhibits PIP3 
(phosphatidylinositol 3,4,5-triphosphate) activity by having protein phosphatase and lipid 
phosphatase activity that is the polar opposite of PI3K (Phosphatidyl Inositol 3-Kinase). 
The aim of this research was to see how often miR-21 and mRNA PTEN were expressed 
at different stages of breast cancer and whether they could be used as prognostic 
markers. This type of research is an observational study with a cross-sectional design. 
The sample size of 43 people came from breast cancer patients. Analysis of miR-21 
expression and mRNA PTEN using Real-Time qPCR. The results showed that miR-21 
expression increased 1.32 times at an advanced stage compared to an early stage, while 
mRNA PTEN expression decreased 1.33 fold at an advanced stage compared to an early 
stage. According to the findings, miR-21 expression in the blood plasma of breast cancer 
patients was upregulated at an advanced stage compared to an early stage and 
downregulated mRNA PTEN expression. MiR-21 which is increased at an advanced 
stage has the potential to be a poor prognostic marker at the stage of breast cancer. The 
change in miR-21 expression can be a good candidate as a molecular prognostic marker 
and for future research the role of miR-21 in breast cancer progression will further enrich 
the scientific repertoire, especially in the health and clinical fields. 
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INTRODUCTION 
Breast cancer is a complicated condition with a wide range of genetic changes. 
Breast cancer is the world's leading cause of death. In 2020, 2.3 million people will be 
diagnosed with breast cancer worldwide, with 685,000 deaths, and 7.8 million women will 
have been diagnosed with breast cancer in the previous five years, making it the most 
common cancer in the world. Breast cancer ranked first among the top five cancers in 
Indonesia in the same year, with 65,858 (16.6 percent) deaths, a mortality rate of 22,430 
(9.6%), and a 5-year prevalence of 201,143 cases (per 100,000) (WHO, 2020). 
Medical Laboratory Technology Journal  
 
 Available online at : http://ejurnal-analiskesehatan.web.id 
ISSN 2461-0879 
 




7(1), 2021, 46-58 
Medical Laboratory Technology Journal | 47 
 
Copyright © 2021, MLTJ, ISSN 2461-0879 
Currently, over several hundred micro RNA (miRNA) have been discovered, and 
variations in miRNA expression have been linked to several cancers, so miRNA profiles 
are used to diagnose or prognosis some cancers, as well as to distinguish certain forms 
of cancer (Yan et al., 2008). MicroRNA modulates gene expression, making it a potential 
diagnostic and prognostic predictor as well as a therapeutic target (Heneghan et al., 
2010). As a result, miRNA is a promising new cancer biomarker in the future (Anwar et 
al., 2020; Mo et al., 2012) 
There has been a decrease in miRNA expression in cancerous tissue relative to 
normal tissue, according to several reports. This means that miRNA can be used to reflect 
a clinical condition as well as a prognostic indicator. Breast cancer patients' prognosis 
may be determined by tumor size, histological rating, and the presence of lymph nodes 
or metastases, so that molecular features can be used to reliably assess the increased 
risk of death or survival in the current malignancy management (Yan et al., 2008). 
Lowery et al. (2009) was the first to show that circulating miRNA can be found in 
cell-free body fluids including plasma and serum. The ability to repeat measurements in 
a non-invasive way, as well as excellent stability in plasma / serum, where they can 
circulate even beyond the exosome and are stable due to binding to the Argonaute 
protein, are all significant advantages of circulating miRNA (Arroyo et al., 2011; Mitchell 
et al., 2008; Turchinovich et al., 2011). 
All human cancers, including breast cancer, have increased expression of MiR-
21, which is the only miRNA that has increased expression (Negrini & Calin, 2008). MiR-
21 has been linked to tumorigenesis, development, and metastasis in tumor 
pathogenesis. Furthermore, miR-21 expression levels are linked to clinical pathologic 
factors and cancer patient prognosis, suggesting that miR-21 may be used as a 
prognostic marker in humans (Anwar et al., 2019; Pan et al., 2010). 
PTEN (Phosphatase Tensin and Homolog) is a tumor suppressor gene that has 
been shown to be missing or mutated in a number of human cancers. PTEN expression 
was found to be reduced in the majority of solid tumors. PTEN expression decreases in 
relation to lymph node metastatic factors, estrogen receptor status, tumor grade, and 
tumor node metastasis (TNM), according to several studies, suggesting that the PTEN 
expression profile may be a very useful prognostic marker in breast cancer (Huang et al., 
2009). PTEN inhibits PIP3 (phosphatidylinositol 3,4,5-triphosphate) activity by having 
protein phosphatase and lipid phosphatase activity that is the polar opposite of PI3K 
(Phosphatidyl Inositol 3-Kinase) activity (Song et al., 2012).  
In Wickramasinghe et al., (2009) study, a decrease in miR21 mediated by 
estrogen was linked to an increase in the expression of the PTEN protein in breast cancer 
cells. Meanwhile, according to Schwarzenbach et al., (2012), PTEN expression is less 
important in determining prognosis in breast cancer, but this is still debatable. PTEN 
expression has been linked to a poor prognosis in certain studies, whereas it has not 
been linked to a bad prognosis in others. 
The difference in the results of several studies related to the expression of mir-
21 and PTEN in breast cancer became the basis for this study. This research aims to 
determine the level of miR-21 and mRNA PTEN expression in patient serum, and 
expected to be a good candidate as a molecular prognostic.  
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MATERIALS AND METHOD 
An observational study with a prevalence study research design is what this sort 
of study is (cross-sectional study). A total of 43 serum samples were taken from female 
patients between the ages of 30 and 70 who had been clinically diagnosed with breast 
cancer but had not received treatment. The patient came from RSUP Dr. Sardjito 
Yogyakarta. This research has been submitted to the Ethics Commission with the 
reference number KE / FK / 60 / EC. The table below shows the primer sequences used 
in this analysis. 
 
Table 1. Target Sequences from Specified Genes 
 
















Extraction of RNA and synthesis of cDNA 
The miRCURYTM RNA Isolation Kit was used to remove total RNA from the blood 
plasma of breast cancer patients (Exiqon Inc, USA). Exiqon's protocol is used for the RNA 
extraction. Furthermore, the kit miRCURY LNA® Universal RT microRNA PCR 
Polyadenylation and cDNA synthesis was used for cDNA synthesis (Exiqon Inc, USA). 
Each PCR reaction for cDNA synthesis had a total volume of 20µL, which included 
nuclease-free water, 10x enzyme mix, 5x reaction buffer, and RNA spike-in template 
(UniSP6). The PCR was performed by incubating the samples at 42°C for 60 minutes and 
then inactivating the reverse transcriptase at 95°C for 5 minutes. Furthermore, before it 
is used for further analysis, the synthesized cDNA is deposited at 4°C. 
 
Real-Time Quantitative Polymerase Chain Reaction (Real-Time qPCR) 
The process two-step Real-Time qPCR was used to examine miR-21 expression. 
Real-Time qPCR was used to detect expression 21 microRNA (CFX96TouchTM RT-PCR, 
Bio-Rad Laboratories, Inc, California, US). The package miRCURY LNA Universal RT 
microRNA PCR, SYBR Green master mix (Exiqon Inc, USA) was used to amplify 
microRNA-21. Primary miR-21 (HSA-miR-21), primary miR-16 as a reference gene, and 
H2O as a negative control were used in the PCR reaction. SYBR® Green, PCR primer 
mix, and cDNA template were used in a total of 10µL PCR reactions per tube (Exiqon Inc, 
USA). Initial denaturation stages of 10 minutes at 95°C, denaturation for 10 seconds at 
95°C, annealing for 1 minute at 58°C, and extension for 5 seconds at 60°C were used in 
the PCR. The stage final extension at 60°C for 5 seconds preceded the end of the loop. 
Biorad CFX ManagerTM Software was used to conduct the analyses. 
The single-method stage Real-Time qPCR was used to analyze miR-21 
expression. mRNA PTEN expression was detected using Real-Time qPCR (CFX96 
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TouchTMRT-PCR, Bio-Rad Laboratories, Inc, California,US). KAPATMSYBR®FASTOne-
Step qRT-PCR Kit was used to amplify PTEN mRNA. Forward and reverse PTEN mRNA 
(hsa-mRNA PTEN) primers, -actin primers as a reference gene, and H2O as a negative 
control were used in the PCR reaction. KAPA SYBR®FAST qPCR Master Mix, forward 
primer, reverse primer, dUTP, KAPA RT Mix, RNA prototype, nuclease-free water make 
up a total of 10µL PCR reactions per channel. Initial denaturation stages of 3 minutes at 
95°C, denaturation for 10 seconds at 95°C, annealing for 30 seconds at 64°C, and 
extension for 5 seconds at 60°C were used in the PCR. The final extension stage at 60°C 
for 5 seconds preceded the end of the cycle. Biorad CFX ManagerTMSoftware was used 
to conduct the analyses. 
  
RESULTS AND DISCUSSION 
Real-Time qPCR analysis of miR-21 and mRNA PTEN 
The Biorad CFX ManagerTM Software was used to perform Real-Time qPCR 
quantification analysis of miR-21 expression and mRNA PTEN. In blood plasma samples 
from breast cancer patients, amplification data from miR-21 as a target and miR-16 as a 
reference gene, as well as mRNA PTEN as a target and β-actin as a reference gene, 
were acquired based on Real-Time qPCR results.  
In Real-Time qPCR, the quantity of amplicon is measured after the amplification 
cycle of each sample ends. The number of amplicons increased with increasing 
fluorescence signal. The average amplification cycles for miR-16 and miR-21 were 26.88 
and 27.04, while those for -actin and mRNA PTEN were 31.00 and 32.75, respectively. 
The miR-21 and mRNA PTEN amplification curves are shown in Figure 1. 
 
Figure 1. Real-Time qPCR amplification curves for miR-21 and mRNA PTEN 
 
Specificity of Real-Time qPCR 
Melting curve in Real Time qPCR reaction shows the dissociation characteristics 
of dsDNA during heating. As the temperature increases, the template dissociates as the 
absorbance intensity increases. The results of the melting curve analysis showed that 
miR-21 and mRNA PTEN were amplified which was characterized by an increase in the 
value of RFU (relative fluorescence unit). The RFU is formed from the luminescence of 
SYBR green as the template amplification reaction increases. The optimum melting 
temperature values for miR-21 were 67.5°C – 68.5°C and 69.5°C – 70°C for miR-16 
(reference gene), while the optimum melting temperature for PTEN mRNA was 81°C – 
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81.5°C and for β-actin (reference gene) it is 79.5°C – 80°C (Figure 2). 
 
 
Figure 2. Melt Curve Analysis of the Expression of miR-21 and mRNA PTEN 
 
Specificity and detection of contamination in real time PCR reactions can be 
identified through a specific melt peak curve at a certain temperature range. Double 
strand DNA (dsDNA) dissociation, which only produces particular melt peaks depending 
on the type of primer used, can be discovered via melt curve and melt peak analysis 
(Figure 3). 
 
Figure 3. Melt Peak Analysis of the Expression of miR-21 and mRNA PTEN 
 
Expression of miR-21 and mRNA PTEN at Early and Advanced Stage 
The threshold cycle (Ct) value is a PCR cycle where the fluorescence signal from 
the dye reporter passes the threshold threshold. The numerical value of Ct is inversely 
proportional to the number of amplicons in the reaction i.e., the lower the Ct value the 
greater the number of amplicons. Data were analyzed by comparative Ct method or better 
known as 2-∆∆Ct. The use of the comparative Ct method is very easy and is able to present 
data in the form of fold changes as a determinant for the expression level of the examined 
gene. The form of the equation fold change (2-∆∆Ct) is used to compare the gene 
expression of two different samples and each sample examined must be linked to its 
internal control gene, namely the reference gene. Ct calculations illustrate the comparison 
of expression between miR-21 in early and advanced stages or mRNA PTEN expression 
in early and advanced stages. If the Ct result is positive (+), it indicates that miR-21 or 
mRNA PTEN has decreased expression (downregulated). If CT is negative (-), it means 
that the expression of miR-21 or mRNA PTEN has risen (up-regulated). If the fold change 
calculation gives a result greater than one, the gene is up-regulated. 
Table 1 shows the expression of miR-21 and mRNA PTEN in terms of advanced 
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and early stages. The fold change value of miR-21 in the advanced stage increased (up-
regulated) 1.32-fold compared to the early stage, while the fold-change value of mRNA 
PTEN in the advanced stage decreased (down-regulated) 1.33-fold compared to the early 
stage. Figure 4 shows the fold change of miR-21 expression and mRNA PTEN in the 
advanced and early stages. 
 
Table 2. Fold Change in miR-21 and mRNA PTEN Expression was Determined Based 
on Stage of the Patients 
 
Variable ΔCt* Fold change P value 
miR-21 
     Advanced Stage 








      Advanced Stage 







ΔCt : The value of Ct is inversely proportional to the relative expression level; if Ct is 






Figure 4. a.The Value of Fold Change miR-21 at an Early Stage and an Advanced 
Stage, b.The Value of Fold Change PTEN mRNA at an Early Stage and  
an Advanced Stage 
 
Expression of miR-21 and mRNA PTEN Based on Molecular Characteristics  
Based on hormone receptors, in ER(-), miR-21 expression was 1.14 times lower 
(downregulated) than in ER(+), and the same thing happened in PR(-), where miR-21 
expression was 1.63 times lower (downregulated) than in PR(+). Expression of miR-21 in 
HER2 (+) increase (up-regulated) 1.38 times compared to HER2 (-). Meanwhile, mRNA 
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happened to PR(-) with an increase of 2.02 times compared to PR(+). mRNA PTEN 
expression in HER2(+) increased 1.60 times compared to HER2(-).Table 2 and Figure 5 
illustrate MiR-21 and mRNA PTEN expression in terms of ER, PR, and HER2 status. 
 
Table 3. The Status of ER, PR, Her2 Showed a Fold Change in miR-21 and  
PTEN mRNA 
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Figure 5b. Fold Change on mRNA PTEN Seen from the Status of ER, PR, Her2 
 
Table 3, the fold change value of miR-21 expression when compared between the 
luminal A subtype and other subtypes, the results of the fold change luminal A vs luminal 
B decreased (downregulated) 1.32 times, luminal A vs Her2 overexpression decreased 
(downregulated) 1.18 times, luminal A vs triple negative increased (up-regulated) 1.45 
times. mRNA PTEN expression when viewed from the luminal A subtype vs other 
subtypes, the results of mRNA PTEN expression in luminal A vs luminal B decreased 
(downregulated) 1.82 times, luminal A vs Her2 overexpression decreased 
(downregulated) 3.12 times, luminal A vs triple negative decreased (downregulated) 2.44 
times. In addition, miR-21 and mRNA PTEN expression in terms of the status of breast 
cancer subtypes can be seen in the form of a diagram as shown in Figure 6. 
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Figure 6b. The Status of Breast Cancer Subtypes Showed a Fold Change  
in PTEN mRNA 
 
MiR-21 expression was up-regulated 1.32 times more in the advanced stage than 
in the early stage, according to the findings. This demonstrates that miR-21 is an 
oncogene that can promote tumor cell growth while also inhibiting apoptosis. Other 
studies have shown that miR-21 is up-regulated in advanced stage (III / IV) breast cancer 
tissue relative to early stage (I / II) breast cancer tissue (M. Li et al., 2010). 
Overexpression of miR-21 is thought to play a role in cell proliferation, migration, and 
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is upregulated in a variety of cancers. In gastric cancer tissue, MiR-21 expression was 
higher than in non-tumor tissue. Furthermore, miR-21 was found to be overexpressed in 
patients with non-small cell lung cancer (NSCLC) (Zhang et al., 2010). Another research 
found that the expression of mir-21 in plasma was substantially associated with miR-21 
expression in tumor tissue in hepatocellular carcinoma (HCC). There have also been 
some functional experiments on miR-21 to show that it has oncogenic activity (Chan et 
al., 2005). 
PTEN is a tumor suppressor gene with phosphatase activity that is mutated in a 
variety of cancers, including breast cancer. PTEN protein expression was decreased by 
38% in invasive cancer and 11% in in situ cancer in breast cancer. In stage II and stage 
III breast cancer, the frequency of PTEN expression decreases dramatically. Expression 
in ductal carcinoma in situ appears to represent the expression pattern of the invasive 
component in tumors with an in situ or invasive component. PTEN expression is 
downregulated in advanced breast cancer, according to these findings. This is supported 
by this research, which found that the expression of mRNA PTEN in plasma was lower in 
advanced breast cancer than in early stage breast cancer (Li et al., 2012). 
Regulation of MiR-21 has steadily increased breast cancer invasion and the growth 
of malignant cancer cells. Anti miR-21 research has also confirmed the relationship 
between miR-21 and PTEN (Li et al., 2012; Meng et al., 2007). As anti miR-21 inhibits 
miR-21 expression, PTEN is expressed, which inhibits Akt phosphorylation, activating 
p21 / WAF1 / CIP1 and p27 / KIP1, as well as Bad defosphorylation, resulting in resistance 
to the G1 / S phase of the cell cycle and triggering apoptosis (Andorfer et al., 2011). 
MiR-21 expression increased in ER+, PR+, and HER2+ based on Real Time qPCR 
study. The findings of this study are in line with those of Radojicic et al.(2011), who 
discovered that miR-21, which is involved in cell development, angiogenesis, proliferation, 
and invasion, is overexpressed in breast cancer. In breast cancer cells, stimulation of 
HER2 signals upregulates miR-21 expression through the MAPK (ERK1 / 2) pathway. 
The activation of MiR-21 by HER2 overexpression will lead to cancer cell invasion and 
metastasis (Huang et al, 2009). Hormone receptors (HR) are expressed in about half of 
breast cancers that overexpress HER2 (Prat et al, 2008). In malignant breast tumors, the 
presence of positive hormone receptors (HR+ / HER2+ causes cell proliferation and 
survival. 
When compared to other breast cancer subtypes, the luminal B subtype had the 
highest miR-21 expression. ER+ breast cancer with increased proliferation was identified 
as subtype luminal B breast cancer in several studies (Cheang et al., 2009). Increased 
expression of the PI3K gene pathway is a major feature of luminal B breast cancer, 
according to a preclinical report, and the inhibition of growth induced by endocrine therapy 
in the luminal B breast cancer cell line can be significantly increased by adding selective 
PI3K inhibitors, suggesting that PI3K inhibitors may play a role (Tran & Bedard, 2011). 
The use of plasma samples as an alternative option in non-invasive molecular 
examinations can be inferred based on the findings of this study because the miRNA and 
mRNA expression patterns are close to those found in breast cancer tissue. Upregulated 
miR-21 expression was found to be oncomer, while downregulated PTEN mRNA 
expression was found to be tumor suppressor, implying that this change in expression is 
essential in the development and progression of breast cancer cells. Since one miRNA 
can target several genes and different miRNAs can target the same gene, it's likely that 
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miR-21 expression rises as a result of its ability to block gene panels that control cell 
proliferation and apoptosis, according to the biogenesis theory of miRNA. MiR-21 
expression and mRNA PTEN were more likely to be associated with poor development 
and prognosis in breast cancer patients, in addition to their association with 
clinopathological and molecular status. Changes in miR-21 expression may be good 
candidates as a molecular prognostic marker for breast cancer progression, according to 
this report, and will contribute to the advancement of research, especially in the health 
and clinical fields. However, this study also has limitations in that it takes a long time at 
the qRT-PCR optimization stage to obtain the optimum temperature and time for the 
analysis of miR-21 and PTEN mRNA. In addition, the number of patient samples for 
advanced stages is less than the sample of patients in the early stages. 
 
CONCLUSION 
According to the findings of this study, miR-21 expression increased 1.32 times in 
the blood plasma of breast cancer patients at an advanced stage relative to the initial 
stage, while PTEN mRNA expression decreased 1.33 times. In terms of molecular status, 
there are variations in the expression levels of miR-21 and PTEN mRNA in breast cancer 
patients based on hormone receptors and subtypes. In future studies, it is necessary to 
conduct research related to the mechanism of interaction between miR-21 and mRNA 
PTEN in plasma / serum of breast cancer patients in terms of clinical and molecular 
status. 
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